Cantor starts Chemomab Therapeutics at OW; PT $45

Cantor Fitzgerald initiated coverage of Chemomab Therapeutics (NASDAQ:CMMB) with an “overweight” rating and $45 price target. The stock closed at $16.07 on May 25.

Chemomab is a clinical-stage biotech company focusing on a pipeline of both rare and highly prevalent fibrotic diseases with high unmet medical needs. The pipeline centers around one candidate, monoclonal antibody, CM-101, that targets the chemokine, CCL24, and can be delivered either intravenously or subcutaneously, writes analyst Kristen Kluska. 

“As a novel target, we think Chemomab’s researchers have conducted extensive preclinical and early-stage clinical testing to validate the dual role CCL24 plays across fibroblast activation and immune cell recruitment,” she added. 

Ms. Kluska said CM-101 has the potential to serve as a “pipeline in a product” and could attract a partnership. 

With three Phase 2a trials expected to be ongoing by the end of the year, “we think there are many near-term inflection points, including two data readouts during the first half of 2022, to drive value to the stock,” she said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.